These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 7579007)

  • 1. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study.
    Goto Y; Hotta N; Shigeta Y; Sakamoto N; Kikkawa R
    Biomed Pharmacother; 1995; 49(6):269-77. PubMed ID: 7579007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
    Shimada H; Miki T; Kyogoku I; Kawagishi T; Inaba M; Okuno Y; Nishizawa Y; Morii H
    No To Shinkei; 1998 Sep; 50(9):817-20. PubMed ID: 9789304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
    Ramirez MA; Borja NL
    Pharmacotherapy; 2008 May; 28(5):646-55. PubMed ID: 18447661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.
    Kawai T; Takei I; Tokui M; Funae O; Miyamoto K; Tabata M; Hirata T; Saruta T; Shimada A; Itoh H
    J Diabetes Complications; 2010; 24(6):424-32. PubMed ID: 19716319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan.
    Hotta N; Sakamoto N; Shigeta Y; Kikkawa R; Goto Y
    J Diabetes Complications; 1996; 10(3):168-72. PubMed ID: 8807467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy.
    Ando H; Takamura T; Nagai Y; Kaneko S;
    J Diabetes Complications; 2006; 20(6):367-70. PubMed ID: 17070440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
    Hotta N; Kawamori R; Fukuda M; Shigeta Y;
    Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.
    Hotta N; Akanuma Y; Kawamori R; Matsuoka K; Oka Y; Shichiri M; Toyota T; Nakashima M; Yoshimura I; Sakamoto N; Shigeta Y
    Diabetes Care; 2006 Jul; 29(7):1538-44. PubMed ID: 16801576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The absence of synergism between the effects of an aldose reductase inhibitor, epalrestat, and a vasodilator, cilostazol, on the nerve conduction slowing and the myelinated fiber atrophy in streptozotocin-induced diabetic rats.
    Sasaki H; Naka K; Kishi Y; Furuta M; Sanke T; Mukoyama M; Nanjo K
    Exp Neurol; 1997 Aug; 146(2):466-70. PubMed ID: 9270057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus.
    Uchida K; Kigoshi T; Nakano S; Ishii T; Kitazawa M; Morimoto S
    Clin Ther; 1995; 17(3):460-6. PubMed ID: 7585850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy.
    Nakayama M; Nakamura J; Hamada Y; Chaya S; Mizubayashi R; Yasuda Y; Kamiya H; Koh N; Hotta N
    Diabetes Care; 2001 Jun; 24(6):1093-8. PubMed ID: 11375376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor.
    Ohi T; Saita K; Furukawa S; Ohta M; Hayashi K; Matsukura S
    Exp Neurol; 1998 Jun; 151(2):215-20. PubMed ID: 9628756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-year inhibition of aldose reductase on development of symptomatic neuropathy in diabetic patients.
    Baba M; Kimura K; Suda T; Yagihashi S;
    J Peripher Nerv Syst; 2006 Jun; 11(2):176-8. PubMed ID: 16787519
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of aldose reductase inhibitor on microneurographically assessed peripheral sympathetic nerve activity in rats.
    Sato D; Kusunoki M; Shinzawa G; Feng Z; Nishina A; Nakamura T
    Auton Neurosci; 2015 Dec; 193():69-73. PubMed ID: 26272532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A placebo-controlled double-blind study of epalrestat (ONO-2235) in patients with diabetic neuropathy.
    Goto Y; Hotta N; Shigeta Y; Sakamoto N; Kito S; Matsuoka K; Takahashi A; Kikkawa R; Sakuma A
    Diabet Med; 1993; 10 Suppl 2():39S-43S. PubMed ID: 8334840
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of the aldose reductase inhibitor, ponalrestat, on diabetic neuropathy.
    Gill JS; Williams G; Ghatei MA; Hetreed AH; Mather HM; Bloom SR
    Diabete Metab; 1990; 16(4):296-302. PubMed ID: 2125013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration.
    Nicolucci A; Carinci F; Cavaliere D; Scorpiglione N; Belfiglio M; Labbrozzi D; Mari E; Benedetti MM; Tognoni G; Liberati A
    Diabet Med; 1996 Dec; 13(12):1017-26. PubMed ID: 8973882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review.
    Schemmel KE; Padiyara RS; D'Souza JJ
    J Diabetes Complications; 2010; 24(5):354-60. PubMed ID: 19748287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of aldose reductase inhibitor on the peripheral nerve function during ischemia in diabetics.
    Kuriya N; Miyake S; Yokota A; Yamaguchi Y; Nakanishi T; Takahashi A; Ueda Y; Mori T; Akiguchi I; Toyama K
    J Med Assoc Thai; 1987 Mar; 70 Suppl 2():168-72. PubMed ID: 3110345
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.
    Vinik AI; Bril V; Kempler P; Litchy WJ; Tesfaye S; Price KL; Bastyr EJ;
    Clin Ther; 2005 Aug; 27(8):1164-80. PubMed ID: 16199243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.